News
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback